Bambusa Therapeutics to Present Phase 1 Data on Bispecific Antibody BBT001 at ISDS 2025

Bambusa Therapeutics Inc has shared an update. The company announced it will present Phase 1 clinical data for BBT001, its novel bispecific IL-4Rα/IL-31 antibody, at the 6th Inflammatory Skin Disease Summit (ISDS 2025) in New York City. The poster, titled “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody: Phase 1 Single-Ascending-Dose Study Results in Healthy Volunteers” (Paper #360), will be featured on November 13, 2025, during an evening poster session at The New York Academy of Medicine. The company highlighted plans to engage with key opinion leaders and to showcase its bispecific antibody platform targeting atopic dermatitis.

For investors, the planned data presentation underscores progress in Bambusa Therapeutics’ clinical pipeline and the advancement of BBT001 beyond preclinical stages. While Phase 1 data in healthy volunteers primarily address safety, tolerability, and pharmacokinetics rather than efficacy, positive results could de-risk the asset and support progression to patient-focused trials in atopic dermatitis, a large and competitive market currently served by established biologics and JAK inhibitors. Visibility at a specialized inflammatory skin disease conference may enhance the company’s scientific profile, aid in partnership or licensing discussions, and potentially strengthen its position when seeking additional funding. However, the financial impact will depend on the quality of the data, subsequent trial design and timelines, and Bambusa’s ability to differentiate BBT001 within a crowded dermatology biologics landscape.